A citation-based method for searching scientific literature

Rune E Kuhre, Seyed M Ghiasi, Alice E Adriaenssens, Nicolai J Wewer Albrechtsen, Daniel B Andersen, Alexander Aivazidis, Lihua Chen, Thomas Mandrup-Poulsen, Cathrine Ørskov, Fiona M Gribble, Frank Reimann, Nils Wierup, Björn Tyrberg, Jens J Holst. Diabetologia 2019
Times Cited: 36







List of co-cited articles
350 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.
Caroline Bonner, Julie Kerr-Conte, Valéry Gmyr, Gurvan Queniat, Ericka Moerman, Julien Thévenet, Cédric Beaucamps, Nathalie Delalleau, Iuliana Popescu, Willy J Malaisse,[...]. Nat Med 2015
360
83

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C Broedl, Hans-Juergen Woerle. J Clin Invest 2014
581
77

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.
Aurora Merovci, Carolina Solis-Herrera, Giuseppe Daniele, Roy Eldor, Teresa Vanessa Fiorentino, Devjit Tripathy, Juan Xiong, Zandra Perez, Luke Norton, Muhammad A Abdul-Ghani,[...]. J Clin Invest 2014
444
69

Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells.
A Solini, G Sebastiani, L Nigi, E Santini, C Rossi, F Dotta. Diabetes Metab 2017
34
50

SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
Takayoshi Suga, Osamu Kikuchi, Masaki Kobayashi, Sho Matsui, Hiromi Yokota-Hashimoto, Eri Wada, Daisuke Kohno, Tsutomu Sasaki, Kazusane Takeuchi, Satoru Kakizaki,[...]. Mol Metab 2019
31
51

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
38

Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion.
Elisa Vergari, Jakob G Knudsen, Reshma Ramracheya, Albert Salehi, Quan Zhang, Julie Adam, Ingrid Wernstedt Asterholm, Anna Benrick, Linford J B Briant, Margarita V Chibalina,[...]. Nat Commun 2019
49
36

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
36

Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells.
Morten Gram Pedersen, Ingela Ahlstedt, Mickaël F El Hachmane, Sven O Göpel. Sci Rep 2016
35
34

Interindividual Heterogeneity of SGLT2 Expression and Function in Human Pancreatic Islets.
Chiara Saponaro, Markus Mühlemann, Ana Acosta-Montalvo, Anthony Piron, Valery Gmyr, Nathalie Delalleau, Ericka Moerman, Julien Thévenet, Gianni Pasquetti, Anais Coddeville,[...]. Diabetes 2020
17
64

Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes.
Per Lundkvist, Maria J Pereira, Prasad G Kamble, Petros Katsogiannos, Anna Maria Langkilde, Russell Esterline, Eva Johnsson, Jan W Eriksson. J Clin Endocrinol Metab 2019
15
66

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
27

Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy.
Robert Martinez, Hussein Al-Jobori, Ali M Ali, John Adams, Muhammad Abdul-Ghani, Curtis Triplitt, Ralph A DeFronzo, Eugenio Cersosimo. Diabetes 2018
31
29

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
25

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
22

CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Ele Ferrannini, Michael Mark, Eric Mayoux. Diabetes Care 2016
462
19

Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes.
Quan Zhang, Reshma Ramracheya, Carolina Lahmann, Andrei Tarasov, Martin Bengtsson, Orit Braha, Matthias Braun, Melissa Brereton, Stephan Collins, Juris Galvanovskis,[...]. Cell Metab 2013
111
19

Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members.
Jian Chen, Sandy Williams, Samantha Ho, Howard Loraine, Deborah Hagan, Jean M Whaley, John N Feder. Diabetes Ther 2010
146
19

Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Ele Ferrannini, Simona Baldi, Silvia Frascerra, Brenno Astiarraga, Tim Heise, Roberto Bizzotto, Andrea Mari, Thomas R Pieber, Elza Muscelli. Diabetes 2016
233
19

Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats.
Rachel J Perry, Aviva Rabin-Court, Joongyu D Song, Rebecca L Cardone, Yongliang Wang, Richard G Kibbey, Gerald I Shulman. Nat Commun 2019
34
20

SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function.
Michael J Jurczak, Hui-Young Lee, Andreas L Birkenfeld, Francois R Jornayvaz, David W Frederick, Rebecca L Pongratz, Xiaoxian Zhao, Gilbert W Moeckel, Varman T Samuel, Jean M Whaley,[...]. Diabetes 2011
139
16


Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
16

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
830
16

Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes.
Åsa Segerstolpe, Athanasia Palasantza, Pernilla Eliasson, Eva-Marie Andersson, Anne-Christine Andréasson, Xiaoyan Sun, Simone Picelli, Alan Sabirsh, Maryam Clausen, Magnus K Bjursell,[...]. Cell Metab 2016
464
16

SGLT2 Inhibitors May Predispose to Ketoacidosis.
Simeon I Taylor, Jenny E Blau, Kristina I Rother. J Clin Endocrinol Metab 2015
244
16

Dysregulation of Glucagon Secretion by Hyperglycemia-Induced Sodium-Dependent Reduction of ATP Production.
Jakob G Knudsen, Alexander Hamilton, Reshma Ramracheya, Andrei I Tarasov, Melissa Brereton, Elizabeth Haythorne, Margarita V Chibalina, Peter Spégel, Hindrik Mulder, Quan Zhang,[...]. Cell Metab 2019
20
30

Dapagliflozin suppresses glucagon signaling in rodent models of diabetes.
May-Yun Wang, Xinxin Yu, Young Lee, Sara Kay McCorkle, Shiuhwei Chen, Jianping Li, Zhao V Wang, Jaime A Davidson, Philipp E Scherer, William L Holland,[...]. Proc Natl Acad Sci U S A 2017
14
35

Regulation of glucagon secretion by glucose: paracrine, intrinsic or both?
J N Walker, R Ramracheya, Q Zhang, P R V Johnson, M Braun, P Rorsman. Diabetes Obes Metab 2011
101
13

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
658
13

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.
R A DeFronzo, J A Davidson, S Del Prato. Diabetes Obes Metab 2012
294
13

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes.
Hassan Rahmoune, Paul W Thompson, Joanna M Ward, Chari D Smith, Guizhu Hong, John Brown. Diabetes 2005
459
13

The GLP1R Agonist Liraglutide Reduces Hyperglucagonemia Induced by the SGLT2 Inhibitor Dapagliflozin via Somatostatin Release.
Chiara Saponaro, Valéry Gmyr, Julien Thévenet, Ericka Moerman, Nathalie Delalleau, Gianni Pasquetti, Anais Coddeville, Audrey Quenon, Mehdi Daoudi, Thomas Hubert,[...]. Cell Rep 2019
13
38

Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.
Sreeneeranj Kasichayanula, Xiaoni Liu, Frank Lacreta, Steven C Griffen, David W Boulton. Clin Pharmacokinet 2014
110
13


Biology of human sodium glucose transporters.
Ernest M Wright, Donald D F Loo, Bruce A Hirayama. Physiol Rev 2011
647
13

Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors.
Mariam Alatrach, Nitchakarn Laichuthai, Robert Martinez, Christina Agyin, Ali Muhammed Ali, Hussein Al-Jobori, Olga Lavynenko, John Adams, Curtis Triplitt, Ralph DeFronzo,[...]. Diabetes 2020
8
62

The New Biology and Pharmacology of Glucagon.
T D Müller, B Finan, C Clemmensen, R D DiMarchi, M H Tschöp. Physiol Rev 2017
105
11

Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains.
Jesper Gromada, Isobel Franklin, Claes B Wollheim. Endocr Rev 2007
369
11

Somatostatin Is Only Partly Required for the Glucagonostatic Effect of Glucose but Is Necessary for the Glucagonostatic Effect of KATP Channel Blockers.
Bao-Khanh Lai, Heeyoung Chae, Ana Gómez-Ruiz, Panpan Cheng, Paola Gallo, Nancy Antoine, Christophe Beauloye, Jean-Christophe Jonas, Victor Seghers, Susumu Seino,[...]. Diabetes 2018
16
25

Islet α cells and glucagon--critical regulators of energy homeostasis.
Jonathan E Campbell, Daniel J Drucker. Nat Rev Endocrinol 2015
127
11

Glucagon Receptor Signaling and Lipid Metabolism.
Katrine D Galsgaard, Jens Pedersen, Filip K Knop, Jens J Holst, Nicolai J Wewer Albrechtsen. Front Physiol 2019
24
16

Effects of intensive glucose lowering in type 2 diabetes.
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
11


Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn,[...]. N Engl J Med 2015
11


Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
Anne L Peters, Elizabeth O Buschur, John B Buse, Pejman Cohan, Jamie C Diner, Irl B Hirsch. Diabetes Care 2015
397
11

SGLT2 inhibition and glucagon secretion in humans.
C Saponaro, F Pattou, C Bonner. Diabetes Metab 2018
16
25

Glucose inhibition of glucagon secretion from rat alpha-cells is mediated by GABA released from neighboring beta-cells.
Anna Wendt, Bryndis Birnir, Karsten Buschard, Jesper Gromada, Albert Salehi, Sabine Sewing, Patrik Rorsman, Matthias Braun. Diabetes 2004
173
11



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.